|View printer-friendly version|
|FDA Expands Clearance of Medtronic Implants for the Treatment of Snoring|
New labeling means more patients can get relief from snoring
MINNEAPOLIS – July 11, 2012 – Medtronic, Inc. (NYSE: MDT) today announced that the FDA has cleared new labeling information for the Pillar Palatal Implant system which is used to help reduce the severity of snoring in patients. While the Medtronic device had been previously approved for the treatment of snoring and sleep apnea, this latest approval allows ENT surgeons to use up to five Pillar Implants specifically for snoring - good news for patients with wider mouths and softer palate tissue.
“The National Sleep Foundation estimates that nearly 90 million American adults are affected by snoring,” said Janis Saunier, marketing director for the Surgical Technologies division at Medtronic, Inc. ”We’re pleased that we can now offer the Pillar Procedure to patients who previously were not candidates.”
This new labeling will allow surgeons to utilize more implants per snoring procedure if it is determined that the patient will have a superior benefit. While FDA has cleared the use of up to five implants for the treatment of snoring, the use of more than three implants for the treatment of mild to moderate obstructive sleep apnea has not yet been studied and is not cleared for use by the FDA.
About The Pillar Procedure
About Medtronic Surgical Technologies
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
– end –Medtronic Media Contacts:
Amy von Walter, Public Relations, 763-505-3780
Jeff Warren, Investor Relations, 763-505-2696